

1.8.2	Ivabradine
Risk Management System	film-coated tablets

VI.2 Elements for a public summary

VI.2.1 Overview of disease epidemiology

Ivabradine is a medicine used for two long-term (chronic) heart conditions: to treat symptoms of chronic stable angina pectoris and to treat chronic heart failure.

Stable angina pectoris (angina) is a heart disease which happens when blood supply to the heart muscle is inadequate, so the heart does not receive enough oxygen. It usually appears between 40 and 50 years of age. The most common symptom of angina is pain in the chest, jaw and back, particularly when the heart beats faster in situations such as exercise, emotion, exposure to the cold or after eating. It is estimated that between 2 and 4% of the population in the EU suffer from stable angina pectoris.

Chronic heart failure is a heart disease in which the heart cannot pump enough blood to the rest of the body. The most common symptoms of heart failure are breathlessness, tiredness and ankle swelling due to fluid build-up. It is estimated to affect between 1 and 2% of the population in the EU.

VI.2.2 Summary of treatment benefits

Chronic stable angina pectoris

Ivabradine has been studied in five main studies involving over 4,000 adults with long-term stable angina. The medicine was compared with placebo (a dummy treatment) in 360 patients, atenolol (a beta-blocker) in 939 patients and amlodipine (another medicine used to treat angina) in 1,195 patients. It was also compared with placebo as an add-on to atenolol in 889 patients and as an add-on to amlodipine in 728 patients. Each study lasted three to four months. The main measure of effectiveness was how long the patients could exercise on a bicycle or a treadmill, measured at the start and the end of each study. The studies showed that the medicine was more effective than placebo at improving exercise capacity and was as effective as atenolol and amlodipine. Ivabradine was also more effective than placebo when added to atenolol. However, adding it to amlodipine did not provide an additional benefit.

Chronic heart failure

Ivabradine has also been compared with placebo in one main study involving 6,558 patients with long-term moderate to severe heart failure. The main measure of effectiveness was the time until death due to disease of the heart or blood vessels, or hospitalisation due to worsening heart failure. It was more effective than placebo at preventing death due to disease of the heart or blood vessels or hospitalisation due to worsening heart failure: 24.5% (793 out of 3,241) of patients treated with ivabradine died or were hospitalised for the first time due to worsening heart failure, compared with 28.7% (937 out of 3,264) of patients treated with placebo.

Another study compared ivabradine with placebo in 19,102 patients with coronary heart disease and without clinical heart failure. The main measure of effectiveness was a reduction in the risk of death due to heart problems and non-fatal heart attack. In this study a specific subgroup of patients who had symptomatic angina had a small but significant increase in the combined risk of cardiovascular death or non-fatal heart attack with Ivabradine compared with placebo (3.4% vs 2.9% yearly incidence rates). However it should be noted that patients in this study were given doses higher than the recommended dose (up to 10 mg twice a day).

RMS001110_1	19.02.2016 - Updated: 19.02.2016 - CONFIDENTIAL	Page 40 of 46
-------------	---	---------------

1.8.2	Ivabradine
Risk Management System	film-coated tablets

VI.2.3 Unknowns relating to treatment benefits

The populations where experience is limited such as patients with renal impairment, patients with hepatic impairment, patients suffering from chronic heart failure and experiencing intraventricular conduction defects t (such as bundle branch blocks) are reflected in the Summary of Products Characteristics.

VI.2.4 Summary of safety concerns

Important identified risks

Risk (organised by system organ class)	What is known	Preventability
Decrease in heart rate (bradycardia)	Decrease in heart rate is a common side effect with ivabradine (seen in between 1 and 10 patients in 100), especially in the first 2 to 3 months after starting treatment. This may lead to dizziness, low blood pressure, fainting, feeling of weakness, feeling of faintness or feeling unwell.	Doctors should follow the dosing recommendations in the product information and not exceed the maximum recommended dose. Treatment must only be started in patients with heart rate above 70 beats per minute, and must be avoided in patients also taking the medicines verapamil or diltiazem.
Luminous visual phenomena (phosphenes/ blurred vision)	Luminous visual phenomena or phosphenes (brief moments of increased brightness, coloured flashes or halos) are very common side effects with ivabradine (seen in more than 1 patient in 10). They are most often caused by sudden changes in light intensity. They generally occur within the first two months of treatment.	The product information contains warnings for doctors and patients about the possibility of luminous visual phenomena, which are linked to the way the medicine works. Patients should be informed that phosphenes resolve during or after treatment with no after effects. If affected, patients should be warned to be careful when driving or using machines at times when there could be sudden changes in light intensity, especially when driving at night.

1.8.2	Ivabradine
Risk Management System	film-coated tablets

<p>Irregular heartbeats (2nd and 3rd degree atrioventricular blocks (AVB II and III))</p>	<p>Irregular heartbeats due to interference with the electrical conduction of the heart are very rare side effects with ivabradine (seen in less than 1 patient in 10,000).</p>	<p>Patients receiving ivabradine will normally have their heart function regularly monitored, particularly when starting treatment or changing dose. The product information contains a warning for doctors that ivabradine is not recommended in patients with existing 2nd degree atrioventricular block and must be avoided in those with existing 3rd degree block.</p>
<p>Uncontrolled blood pressure (increase in blood pressure in hypertensive patients)</p>	<p>Uncontrolled blood pressure is a common side effect with ivabradine (seen in between 1 and 10 patients in 100). This may happen in patients suffering from hypertension (high blood pressure), especially after a change in their blood pressure treatment.</p>	<p>The product information for ivabradine warns doctors that when blood pressure treatment is modified in chronic heart failure patients treated with ivabradine, their blood pressure should be monitored at an appropriate interval.</p>
<p>Irregular rapid contractions of the upper chambers of the heart (atrial fibrillation)</p>	<p>Atrial fibrillation (a rapid, irregular rhythm of the upper chambers of the heart) is a common side effect with ivabradine (seen in between 1 and 10 patients in 100).</p>	<p>The product information states that patients should be informed of signs and symptoms of atrial fibrillation (such as high pulse rate when resting, or irregular pulse rate) and be advised to contact their doctor if these occur.</p> <p>If atrial fibrillation develops during treatment, the balance of benefits and risks of continued ivabradine treatment should be carefully reconsidered.</p>

1.8.2	Ivabradine
Risk Management System	film-coated tablets

Abnormal ECG heart tracing (prolonged QT interval on ECG)	A type of abnormal ECG heart tracing known as QT prolongation (reflecting a change in the electrical activity of the heart) is an uncommon side effect with ivabradine (seen between 1 and 10 patients in 1,000). This event is linked to the effect of ivabradine in lowering heart rate.	The product information warns doctors that use of ivabradine in patients with inborn alteration in QT interval (congenital QT syndrome) or with other medicines that may also prolong QT interval should be avoided if possible. If ivabradine is used in such circumstances close monitoring of heart function is needed.
--	--	--

Important potential risks:

Risk	What is known (Including reason why it is considered a potential risk)
Irregular contractions of the upper chambers of the heart (supra-ventricular tachyarrhythmia other than atrial fibrillation)	Based on clinical trial data, supra-ventricular tachyarrhythmia (fast, irregular contractions of the upper chambers of the heart) of types other than atrial fibrillation could occur. However, studies performed in current medical practice reported a similar risk in patients treated with ivabradine and patients given placebo (dummy treatment).
Immune disorders	Based on data in animals, ivabradine may cause shrinkage of the thymus gland, which plays a role in the immune system (the body's natural defences). Studies in humans have not so far shown any role of the medicine in the occurrence of immune disorders.
Severe irregular contractions of the lower chambers of the heart (severe ventricular arrhythmia)	Based on post-marketing data, severe ventricular arrhythmias may happen in patients with different risk factors or taking other drugs. However, clinical studies in humans have not so far shown an increased risk in patients treated with ivabradine.
Heart attack (myocardial infarction)	Based on the preliminary results of a large clinical study called SIGNIFY, in which ivabradine was given differently than currently authorised, severe slowing of heart rate (bradycardia) caused by the medicine could lead to

RMS001110_1	19.02.2016 - Updated: 19.02.2016 - CONFIDENTIAL	Page 43 of 46
-------------	---	---------------

1.8.2	Ivabradine
Risk Management System	film-coated tablets

	myocardial infarction.
--	------------------------

Missing information:

Risk	What is known
Limited information on use in children under 18 years old	The effectiveness and safety of ivabradine have not been studied in this population.
Limited information on use in pregnancy and breastfeeding women	The effectiveness and safety of ivabradine have not been studied in this population. Ivabradine must not be used during pregnancy or breastfeeding as studies in animals suggest it can harm the unborn child. Women who are able to have children should use appropriate contraceptive measures while taking the medicine.
Limited information on use in patients with severely reduced liver function (hepatic insufficiency)	The effectiveness and safety of ivabradine have not been studied in this population and it is recommended that they should not be given the medicine,
Limited information on use in patients with severely reduced kidney function (renal impairment)	The effectiveness and safety of ivabradine have not been studied in this population and it should be used with caution.
Limited information on use in chronic heart failure patients with intra-ventricular conduction defects	The effectiveness and safety of ivabradine have not been fully studied in this population.

VI.2.5 Summary of additional risk minimisation measures by safety concern

All medicines have a Summary of Product Characteristics (SmPC) which provides physicians, pharmacists and other health care professionals with details on how to use the medicine, the risks and recommendations for minimising them. An abbreviated version of this in lay language is provided in the form of the package leaflet (PL). The measures in these documents are known as routine risk minimisation measures.

The Summary of Product Characteristics and the Package leaflet for this product can be found at the national agencies' webpages.

This medicine has no additional risk minimisation measures.

VI.2.6 Planned post authorisation development plan (if applicable)

RMS001110_1	19.02.2016 - Updated: 19.02.2016 - CONFIDENTIAL	Page 44 of 46
-------------	---	---------------

1.8.2	Ivabradine
Risk Management System	film-coated tablets

Not applicable. No postauthorisation studies are planned.

VI.2.7 Summary of changes to the Risk Management Plan over time

Not applicable, this is the first Risk management plan.

1.8.2	Ivabradine
Risk Management System	film-coated tablets

Part VII- Annexes

Annex 1 – Eudravigilance

Not applicable.

Annex 2 - SmPC & Package Leaflet

Please see attached document.

Annex 3 - Worldwide marketing authorisation by country (including EEA)

Not applicable yet.

Annex 5 - Synopsis of pharmacoepidemiological study

Not applicable.

Annex 6 - Protocols for proposed and on-going studies in Part III

Not applicable.

Annex 7 - Specific adverse event follow-up forms

Not applicable.

Annex 8 - Protocols for studies in Part IV

Not applicable.

Annex 9 - Synopsis of newly available study reports in Parts III-IV

Not applicable.

Annex 10 - Details of proposed additional risk minimisation activities

Not applicable.

Annex 11 - Mock up examples

Not applicable.

Annex 12 Other supporting data

Not applicable.

RMS001110_1	19.02.2016 - Updated: 19.02.2016 - CONFIDENTIAL	Page 46 of 46
-------------	---	---------------